Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Biogen CEO said no risky deals in 2023. Now he’s ready to be bold
While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines.
Annalee Armstrong
Aug 1, 2024 10:34am
Biogen walks away from Denali Alzheimer's collab
Aug 1, 2024 10:27am
Biogen, Sage flunk midphase essential tremor trial, stop study
Jul 24, 2024 8:10am
Top 10 smartest deals in biopharma
Jun 24, 2024 6:00am
FDA lays out donanemab concerns, Lilly vigorously defends safety
Jun 6, 2024 10:55am
Taking ALS therapies beyond 'a shot in the dark'
May 29, 2024 1:51pm
